EMA Authorised: Doptelet (avatrombopag maleate) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

EMA authorised Doptelet (avatrombopag) for the treatment of thrombocytopenia in the European Union; decision date 22 May 2025. Marketing authorization holder: S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• DOPTELET (avatrombopag)

Snippet

Status: Authorised. Therapeutic area: Thrombocytopenia. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 22/05/2025